Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
(NASDAQ:PLRZ), Eurofins CDMO Amatsiaquitaine S.A.S., the GMP manufacturer, to support Polyrizon in future commercialization efforts Raanana, Israel, Jan. 23, 2025 (GLOBE NEWSWIRE) — Polyrizon Ltd. (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announces today it has commenced preliminary work related to the Good Manufacturing Practice […]